TABLE 1.
Subject characteristics.
| Control | PD | Test | |
| Number | 16 | 19 | n/a |
| Sex (n, %) | |||
| Male | 4 (25%) | 13 (68%) | p = 0.03‡ |
| Female | 11 (69%) | 6 (32%) | |
| Not reported | 1 (6%) | 0 (0%) | |
| Age (years) | |||
| Average | 66.4 | 66.8 | p = 0.87† |
| Range | 56–80 | 55–81 | |
| Race (n,%) | |||
| Caucasian | 13 (81%) | 18 (95%) | p = 0.28‡ |
| African-American | 1 (6%) | 1 (5%) | |
| Not reported | 2 (13%) | 0 (0%) | |
| BMI | |||
| Average | 26.8 | 28.0 | p = 0.68† |
| Range | 20–35 | 20–48 | |
| Age at PD onset (years) | |||
| Average | n/a | 56.1 | n/a |
| Range | n/a | 45–74 | |
| Disease duration (years) | |||
| Average | n/a | 11.4 | n/a |
| Range | n/a | 7–18 | |
| MDS-UPDRS | |||
| Average | n/a | 17.0 | n/a |
| Range | n/a | 0–37 | |
| H&Y | |||
| Median | n/a | 2 | n/a |
| Range | n/a | 2–3 | |
| Medication (n,%) | |||
| Dopamine precursor | – | 19 (100%) | |
| Dopamine agonists | – | 10 (53%) | n/a |
| Glutamate antagonist | – | 8 (42%) | |
| Anticholinergics | – | 2 (11%) | |
| COMT inhibitors | – | 4 (21%) | |
| MAO-B inhibitors | – | 7 (37%) | |
| Antidepressant | – | 1 (5%) | |
‡Chi square analysis.
†Student’s t-test.